Unitedhealth Group Inc Earnings - Q2 2026 Analysis & Highlights
UnitedHealth Group's Q2 2026 earnings call focused on improved operational performance across its businesses, elevated medical cost trends particularly in commercial segments, strategic investments in AI and modernization initiatives, and updated full-year guidance reflecting stronger-than-expected results in Medicare Advantage and Optum Health.
Key Financial Results
Adjusted earnings per share of $6.38 compared to $4.08 in the prior year.
Total revenues were $112 billion, largely consistent with the prior year, while operating earnings of $8 billion grew 55% year-over-year.
Medical care ratio of 86.7% includes $860 million of net favorable prior period medical development, compared to 89.4% in Q2 2025.
Operating cost ratio was 12.7% for the quarter, compared to 12.3% a year ago.
Operating cash flows in the quarter were approximately $11 billion, or 1.9 times net income.
Days claims payable was 47 days, up approximately 2.5 days from a year ago.
Business Segment Results
UnitedHealthcare overall performance in the second quarter exceeded expectations, driven by better results in Medicare Advantage while commercial benefits remain pressured.
Medicare Advantage delivered a strong second quarter with membership retention better than previously anticipated, and the company now expects full year Medicare Advantage enrollment to decline by approximately 1.1 million, with Medicare margins to finish 2026 above 3%.
Medicaid overall performance during the quarter, including cost trend, was broadly in line with expectations, with margins expected to remain within the previously communicated range of negative 1% to negative 1.7% for 2026.
Commercial benefits continue to experience higher than expected cost trends with medical cost trends modestly above 11%, driven by pressure from the independent resolution process under the No Surprises Act and more aggressive billing practices among providers.
Optum Health is seeing building momentum as the business re-centers back to its integrated value-based care delivery model, with patient experience in care delivery sites up approximately 5% year-over-year and patient access expanded by nearly 200,000 more patient facing hours.
Optum Rx continues to perform to plan with retention rates in the high-90s, and the company expects to end 2026 with more than 95% of clients on a 100% pass-through of manufacturer rebates.
Optum Insight is on plan and remains on a multiyear path of reinvestment and innovation, with AI-enabled approaches gaining traction among payer and provider customers.
Capital Allocation
Through mid-July, the company deployed $4 billion for repurchases of 11.4 million shares, and now expects to complete total share repurchases of at least $5 billion in 2026, compared to initial guidance of $2.5 billion.
During the quarter, the company returned $2.1 billion to shareholders through its dividend, which the board increased to $9.28 per share on an annualized basis.
On July 2, the company successfully closed the previously announced combination with Alegeus.
Debt-to-capital ratio was 41.2% at the end of the quarter, compared to 44.1% one year ago and a 170-basis-point sequential improvement from the first quarter of this year, with the company remaining on track to reduce its debt-to-capital ratio to approximately 40% by the end of 2026.
Industry Trends and Dynamics
Medical cost trends remain very high across all product lines when compared to historical levels, with Medicare medical cost trends still running well above historical levels but below initial expectations for 2026.
Medicaid trend remains elevated versus pre-pandemic levels but stable, with continued pressure in specialty pharmacy, home and community based services, behavioral healthcare services, and inpatient and SNF costs for complex populations.
Commercial medical cost trends are stubbornly high and rising above expectations, which the company believes is consistent with what is being experienced across the sector.
The independent resolution process (IDR) under the No Surprises Act is being exploited by select providers and select geographies, contributing approximately 50 basis points of incremental trend in 2026, totaling at least 100 basis points of total cost.
Provider coding intensity with office visits, emergency departments, and selective other care sites being primary drivers is contributing incremental trend to last year and to expectations.
Specialty pharmacy costs reflect both higher net costs and growth of newly covered indications, with anti-inflammatory and GLP-1 drugs being part of the mix.
Stars program has continued to get more challenging in recent years, as evidenced by 2026 industry scores at the lowest level in about a decade.
Competitive Landscape
Optum Rx continues to win new customers and retain existing ones with retention rates in the high-90s through leading an industry-wide shift toward transparency and fee-based services.
The company is strategically aligned with payer partners on value-based care, which improves quality, lowers the total cost of care, improves the experience for patients, and improves the experience for clinicians.
Optum Health reaches nearly 90% of US counties and conducts approximately 2.5 million rural patient home visits annually.
Macroeconomic Environment
The company accommodated for some level of potential unknown risk elements in its planning, such as tariffs and other things of that nature, but has not seen the full emergence of material unknown elements at this stage.
The company remains respectful of medical trend and believes the refreshed outlook appropriately balances risk and investments with durable run-rate earnings.
Growth Opportunities and Strategies
AI technology is helping the company move faster, improve service interactions, reduce administrative burden, and support better decision making in service of improved experiences and outcomes for both patients and care providers.
The company is committed to eliminating by the end of this year, 30% of prior authorization volume and nearly two-thirds of prior authorization requirements for pediatric care.
UnitedHealthcare is modernizing essential healthcare experiences to improve how consumers and care providers experience the health system through simplifying prior authorization, increasing consumer responsive digital experiences, providing greater support to rural hospitals and care providers, and offering more consumer centered product innovation.
Optum Health is advancing approaches that better support care providers and drive measurable improvements to patient care at lower cost, including enhanced support for patients during key transitions of care resulting in approximately 10% reduction in hospitalizations, home health initiatives driving more than 20% improvement in timely care delivery, and expanded access to care in rural health through integrating house calls and home-based care capabilities.
AI-based ambient listening capabilities are available to 70% of Optum Health's employed providers today, and on track to exceed 90% by year-end.
Optum Rx announced a new pharmacy care approach based on monthly per member fees with full PBM and GPO fee transparency and enhanced consumer tools.
Optum Insight is bringing AI-enabled tools and services to market, including solutions such as AI-enabled coding, real-time payer and provider interfaces, and clinical quality and safety support.
The company is focused on serving consumers and care providers in ways that are reliable, affordable and transparent through simplifying processes, being clear, more consistent and faster in the experience offered, and redesigning and modernizing that experience altogether.
Value-based care approaches are a key component of the effort to make healthcare more affordable by bending the cost trend and better aligning incentives for both consumers and care providers.
Financial Guidance and Outlook
Adjusted earnings per share guidance range of $19.50 to $20 for full year 2026, with slightly more earnings in Q3 relative to Q4.
Full year operating earnings outlook for UnitedHealthcare increased to at least $12 billion and for Optum Health to at least $2.2 billion.
Full year medical care ratio expected to be 88.1%, plus or minus 25 basis points.
Operating cost ratio expected to come in at the higher end of previously discussed range, as a result of investments in people, communities and AI.
2026 Medicare medical cost trend expected to come in below initial estimate of around 10%.
Medicaid margins expected to remain pressured for 2026, with annualized 2026 rate impacts expected to be in the zone of around 6% to 7% and still lagging elevated medical trend.
Commercial margin recovery will remain a focus area longer than originally anticipated, with the company seeing 2026 as a delay to margin recovery trajectory, not a setback, and remaining confident in returning to historic margin performance of 7% or greater for the commercial group business.
UnitedHealthcare earnings continue to be weighted approximately 75% to the first half of the year.
Optum Health earnings expected to be nearly all recognized in the first half with modest profit in Q3, offset by modest losses in Q4, due to seasonality of risk-based businesses.
Optum Insight and Optum Rx remain more heavily weighted towards the second half of the year, with each expected to generate approximately 55% of their full year earnings during the back half.
Overall earnings cadence expected to be a two-thirds/one-third first half to back half mix.
The company continues to believe in the 13% to 16% long-term growth rate and believes it can perform in that growth rate range.
Healthcare System Modernization and Quality
The company is focused on essential themes of affordability, transparency, modernization, simplicity, and convenience.
The company views quality as absolutely critical and is restless when it comes to seeking opportunities to differentiate, always focused on delivering the greatest quality experiences and outcomes for members.
The company remains fully committed to its quality agenda and is investing in that more than ever, including in the second half of the year to support various quality programs and initiatives for members and providers.
AI-powered digital prior authorization is producing 96% first-pass approval, enabling humans to review denials while making the system simpler, better, and faster for providers and patients.
Ambient clinical documentation using AI is reducing cognitive burnout for clinicians by 90%, helping them deliver care better to patients.
The company is committed to processing 80% of prior authorizations in real-time by the end of 2027, creating a touchless environment that eliminates back and forth between health systems, care providers and health plans.
